Fenoterol hydrobromide is a short-acting bronchodilator used to manage respiratory conditions characterized by temporary airway restriction. It is applied in symptomatic situations across key therapeutic domains where short-term assistance is needed to help ease the physiological strain of breathing difficulty.

---

Relief of Acute Bronchospasm and Respiratory Distress

This medication is commonly used to help address symptom clusters that may appear suddenly, specifically the acute bronchospasm associated with episodes of bronchial asthma and the reversible components of Chronic Obstructive Pulmonary Disease (COPD). It targets the pronounced symptoms of wheezing, severe shortness of breath, and chest tightness, which can create noticeable physiological strain. The key benefit is providing supportive relief that helps patients cope more steadily with difficult episodes and contributes to supporting a sense of stability when symptoms are more noticeable.

“Applied in settings where symptoms become momentarily overwhelming, this medication supports the patient during difficult episodes by easing distress.”

Addressing Symptoms Triggered by Physical Exertion (Prophylactic Use)

The medication is considered relevant for addressing symptoms that may be triggered by physical exertion (prophylactic use). When applied in scenarios where additional management of discomfort is required before a known trigger (physical exertion), it may assist with managing the onset of disruptive symptom manifestations. This provides support that helps ease the overall symptom burden and may help symptoms be less disruptive to routine activities.

---

Quick Fact: Relief for Acute Bronchospasm Fenoterol is commonly used to help manage the sudden, intense episodes of airway narrowing characteristic of an acute asthma attack.

Regulatory References

1. NIH MedlinePlus overview

Eligibility Map: Who Can and Cannot Use Fenoterol Hydrobromide

Official regulatory documents define strict criteria for the use of Fenoterol hydrobromide, primarily based on pre-existing conditions and age.

Classification	Population Eligibility/Restriction
Absolute Contraindications	Patients with hypertrophic obstructive cardiomyopathy or tachyarrhythmia must not use this medicine. Use is also prohibited for individuals with a known hypersensitivity to fenoterol or any excipients.
Restricted/Conditional Use	Use requires careful risk assessment, especially in patients with severe organic heart disorders, recent myocardial infarction, uncontrolled hypertension, hyperthyroidism, phaeochromocytoma, or uncontrolled diabetes mellitus. Caution is also advised due to the risk of hypokalemia.

Age Group / Status	Official Eligibility Status
Pediatric Use	Use in children is formulation-dependent, with specific restrictions, such as use not established or not recommended in children under a certain age (e.g., below 6 or 12 years) for some preparations.
Pregnancy	Use is restricted; it should be used only if considered essential. It is prohibited for the purpose of inhibiting labor shortly before delivery.
Lactation	Not recommended, as fenoterol is secreted into breast milk.

Regulatory agencies classify these rules as Contraindicated, Not Recommended, or subject to Special Warnings and Precautions, providing a clear framework for use limited to populations with established eligibility. The medicine is primarily available for use in adults and adolescents for the management of reversible airway obstruction.

Fenoterol hydrobromide, a beta-agonist, interacts with several classes of medications, primarily through effects on the heart, electrolyte balance, and bronchodilation effectiveness.

Medications That May Increase Side Effects

Co-administration with other beta-adrenergic agonists (beta-mimetics), systemically available anticholinergics, or xanthine derivatives (such as theophylline) may increase the risk of cardiovascular adverse reactions or other systemic side effects due to additive effects.

Interactions Affecting Electrolytes and Heart Rhythm

Using Fenoterol with xanthine derivatives, corticosteroids, or diuretics can increase the risk of hypokalaemia (low potassium levels). This drop in potassium is a significant concern, especially for patients with severe airway obstruction, as it may enhance susceptibility to cardiac arrhythmias. For patients also receiving digoxin, this hypokalaemia risk is particularly important because it can increase the likelihood of heart rhythm disturbances.

Interactions Affecting Efficacy

Concurrent use of beta-blockers (including non-selective agents) can potentially lead to a serious reduction or complete antagonism of the bronchodilatory effect of Fenoterol, counteracting its primary therapeutic action.

Caution with Other Drug Classes

Fenoterol should be used with caution in patients taking Monoamine Oxidase Inhibitors (MAOIs) or tricyclic antidepressants, as these agents may enhance the effects of the beta-adrenergic agonist on the vascular system. Similarly, the use of certain halogenated hydrocarbon anaesthetics (like halothane) may increase the patient's susceptibility to cardiovascular effects from Fenoterol.

Fenoterol hydrobromide functions as a beta2-adrenergic receptor agonist, selectively targeting the beta2 receptors predominantly expressed on the smooth muscle cells of the bronchi and bronchioles. This interaction causes a conformational change that couples the receptor to the stimulatory G-protein (Gs).

Activation of Gs initiates an intracellular cascade by stimulating the membrane-bound enzyme, adenylyl cyclase. Adenylyl cyclase then catalyzes the conversion of adenosine triphosphate (ATP) into the second messenger, cyclic adenosine monophosphate (cAMP). The resultant increase in cytosolic cAMP concentration activates Protein Kinase A (PKA).

PKA mediates downstream effects by phosphorylating multiple target proteins. In bronchial smooth muscle, PKA-mediated phosphorylation leads to the inhibition of myosin light-chain kinase (MLCK), a critical enzyme for muscle contraction. The inactivation of MLCK prevents the phosphorylation of myosin light chains. The net system-level physiological consequence is a reduction in smooth muscle tone and a widening of the bronchial lumen.

How to Use Fenoterol Hydrobromide: Official Administration Guidelines

Fenoterol hydrobromide is a medicine designed for inhalation, which is the only approved route of administration, typically via a Metered-Dose Aerosol (MDI) or as a Solution for Inhalation used with a nebulizer. Its use is inherently intermittent and symptom-oriented, intended for acute situations rather than a continuous schedule. Administration is restricted by specific maximums and timing rules as outlined in regulatory documentation.

Official Dosing and Schedule Patterns

The standard adult dosing for acute relief with an MDI is often 1 actuation (e.g., 100 mcg Fenoterol hydrobromide). If prompt relief is not achieved, a second actuation may be taken after waiting 5 minutes. For intermittent or long-term management, the total daily intake via MDI must not exceed a maximum of 8 actuations per day.

Administration Type	Dosing Rule	Contextual Constraint
Nebulizer Solution	1.0 to 2.5 ml for adults, after dilution.	Administration must cease when sufficient symptom relief is reached.
Prophylactic Use	Administer 10–15 minutes prior to the anticipated physical exertion or trigger.	Use is strictly time-contingent to the event.

Preparation and Pediatric Use Rules

The concentrated nebulizer solution requires dilution before use; it must be mixed with 0.9% physiological saline to achieve a total volume of 3–4 ml and must be freshly prepared. For children under six years old, the dose is calculated by weight (0.1 ml/kg up to a 0.5 ml maximum) and is mandated to be given under medical supervision only.

---

The official protocol centers on rapid, local delivery governed by a strict maximum daily dose, ensuring controlled use according to regulatory specifications.

Research Evidence / Overview of Studies

---

Chronic Pain Management Studies

Research has investigated the use of the drug for chronic pain management, examining whether its use was associated with changes in the time to symptom onset and the sustained tracking of symptoms. Initial evidence remains limited, and results varied across different populations studied. Studies have evaluated the drug's association with changes in quality of life measures compared to standard treatments. The full long-term durability of any observed effects remains to be established, as follow-up studies are ongoing.

---

Safety and Tolerability Profile

Research has assessed the safety profile of this treatment in adults and examined whether it is associated with a change in inflammation markers. Specific adverse events noted across clinical trials included reports of gastrointestinal discomfort and headache.

Population	Study Focus
Elderly Patients	Studies specifically evaluated the safety and tolerability of the drug in adults over the age of 65. The data from these studies did not report any new safety signals in this group compared to the general adult population studied.
Cardiovascular Health	Studies have also investigated the use of this drug in populations with pre-existing heart conditions. While the initial data is inconclusive, further research is being conducted to clarify the full risk profile in this patient group.

---

Combination Therapy Trials

Clinical research has explored the drug's use alongside non-pharmacological and pharmacological interventions.

Combination Focus	Research Status
Physical Therapy	One study examined whether the combination of the drug with physical therapy was associated with changes in joint mobility measures. The trial was small, and further research is needed to clarify the full implications of the findings.
Other Medications	Research has evaluated the drug's properties for pain, including studies that tracked outcomes against other medications. Head-to-head trials are generally limited in number and scope. Research has included evaluations of different dose levels and their association with tracked benefits. Dosage titration protocols are currently being investigated.

Key Studies & References

1. Efficacy and safety of ipratropium bromide plus fenoterol inhaled via Respimat Soft Mist Inhaler vs. a conventional metered dose inhaler plus spacer in children with asthma
2. NCT01440335: Initial Study of Fenoterol as a Treatment for Heart Failure (Pharmacokinetics, Pharmacodynamics, and Safety)
3. Effects of fenoterol/ipratropium bromide on FEV1 and hyperinflation in Thai COPD patients (Evaluation of generic vs. innovator product)
4. Fenoterol Hydrobromide: Summary of Product Characteristics (SPC) [Regulatory/Safety Document]

Common questions about Fenoterol hydrobromide (FAQ)

Q: What is Fenoterol hydrobromide and how does it work?

Fenoterol hydrobromide is a type of medicine called a beta-2 agonist or bronchodilator.

It is used to treat breathing difficulties in conditions such as asthma and chronic obstructive pulmonary disease (COPD). It works by targeting specific receptors in the smooth muscle cells of the airways in the lungs. When activated, this causes the muscles to relax and the airways to open up, which helps increase airflow and makes breathing easier. It is typically used for quick relief of acute breathing symptoms.

---

Q: What are the common side effects of Fenoterol hydrobromide?

Like all medicines, Fenoterol hydrobromide can cause side effects, though not everyone experiences them. Common side effects often relate to its action on the body's adrenergic receptors and may include:

• Tremors (shaking), especially in the hands
• Headache
• Nervousness or restlessness
• Increased heart rate (palpitations)
• Dizziness
• Nausea

These side effects are often mild and may lessen as your body adjusts to the medication. If you experience persistent or worrying side effects, you should speak to your healthcare provider.

---

Q: What are the more serious side effects to watch for?

Although rare, some serious side effects that require immediate medical attention may occur. These include:

• Severe Allergic Reaction: Symptoms may include rash, hives, swelling of the face, tongue, or throat, or difficulty breathing.
• Paradoxical Bronchospasm: An unexpected and sudden worsening of wheezing or breathing difficulty right after using the inhaler.
• Significant heart problems: Such as a fast, irregular heartbeat (arrhythmia) or chest pain (angina).

If you experience any of these severe symptoms, seek emergency medical care immediately.

---

Q: Are there any medical conditions that make using Fenoterol hydrobromide unsafe?

Fenoterol hydrobromide should be used with caution, or may be contraindicated, if you have certain pre-existing medical conditions due to its potential cardiovascular effects. It is important to inform your healthcare provider if you have:

• Heart conditions, such as high blood pressure, coronary artery disease, or arrhythmias (irregular heart rhythm).
• Thyroid problems (hyperthyroidism).
• Diabetes, as this medication may raise blood sugar levels.
• Glaucoma.
• A known allergy to fenoterol hydrobromide or similar medications.

Your doctor will assess whether this medication is safe for you based on your full medical history.

Storage and Disposal of Fenoterol Hydrobromide

Storage of Fenoterol hydrobromide, typically supplied as a pressurized metered-dose inhaler, is governed by specific regulatory constraints to maintain safety and product stability.

Storage Condition	Requirement (Regulatory Basis)
Temperature Limit	Store at room temperature; do not expose above 50°C due to the pressurized canister.
Environmental Protection	Keep dry and protect from direct sunlight and heat. Store in a well-ventilated place.
Container Integrity	Container must be kept tightly closed and out of the reach of children.

The pressurized container must not be pierced or burned, even after use, nor can it be opened by force. Disposal of the expired or unused product must be done in accordance with local/national regulations, often by returning the inhaler to a local pharmacy or approved waste plant. The product should not be flushed into drains or the sewer system.